CD123 Assay Portfolio Service
The Biology of CD123
Fig.1 The interleukin-3 (IL-3) receptor. (Reddy, 2000)
CD123, also known as interleukin-3 receptor α (IL-3Rα), is a type I transmembrane glycoprotein. CD123 forms dimers with IL-3 receptor β (IL-3Rβ), CD131, and triggers a series of downstream cell signaling pathways via JAK2 and STAT5. The molecular weight of the CD123/IL-3Rα chain is 75kD. CD123 is expressed in basophils, dendritic cells, monocytes, myeloid progenitors of normal hematopoietic cells, and endothelial cells, to induce tyrosine phosphorylation, proliferation, and differentiation within a cell. CD123 antigen facilitates transmission of the signal of IL-3, an important soluble cytokine in the immune system. CD123 antigen is highly expressed on a variety of cells from many hematologic malignancies. Therefore, CD123 has emerged as an attractive immunotherapeutic target for the treatment of CD123 hematologic malignancies.
CD123 Expression in Hematologic Malignancies
In malignancies, CD123 is abnormally expressed in myelodysplastic syndrome, acute myeloid leukemia (AML), B/T-acute lymphoblastic leukemia, and Hodgkin lymphoma (HL). Thus, CD123 can be a novel biomarker for diagnosis and monitor. CD123 is strongly expressed on AML leukemic blasts and leukemic stem cells (LSCs, 98 ± 2%) whereas being restricted to <1% on normal hematopoietic stem cells (HSCs). Different studies have shown CD123 is expressed in 45-95% of AML cases. Some studies have identified that CD123 shows expression in classical HL Reed-Sternberg cells and tumor-associated macrophages which are related to treatment response. Stable expression of CD123 in residual leukemic cells during early therapy makes it a suitable biomarker for minimal residual leukemic surveillance. Moreover, the high expression of CD123 in acute lymphoblastic leukemia may provide an important therapeutic target.
CD123-targeted Therapies
Clinical data indicates that high CD123 expression in hematologic malignancies is associated with poor prognosis and reduced survival rate. A number of CD123-targeted therapies have been developed over the past decades including:
-
Monoclonal antibodies against CD123;
-
Bispecific antibody-based molecules;
-
CD123-targeting antibody-drug conjugate;
-
Chimeric antigen receptor T cell therapy (CART).
Fig.2 Schematic diagram of various CD123-targeted therapeutic constructs. (El Achi, 2020)
What Can We Offer?
Creative Biolabs provides the most comprehensive and detailed services and products for tumor marker assay. We are committed to providing reliable and easy-to-use solutions and services to meet the needs of current research. With years of experience and expertise in high-quality platforms, we can provide several CD123 assay portfolio services listed as following.
-
CD123 blockade assay
-
Cell proliferation assay
-
Apoptosis assay
-
Cytotoxicity assay
-
Cell differentiation assay
-
Immunofluorescence and immunohistochemistry assay
-
Flow cytometry
-
Immunoblotting
-
ELISA assay
At Creative Biolabs, our assays are not limited to the description above. In addition, we offer customized assays based on the needs of each client and can assist clients in designing studies to speed the progression of clients' projects. If you don’t find profiling that suits your needs, don’t hesitate to contact us or send us your inquiry or question.
References
-
Reddy, E.; et al. IL-3 signaling and the role of Src kinases, JAKs and STATs: a covert liaison unveiled. Oncogene, 2000, 19(21): 2532-2547.
-
El Achi, H.; et al. CD123 as a biomarker in hematolymphoid malignancies: principles of detection and targeted therapies. Cancers, 2020, 12(11), 3087.
For Research Use Only | Not For Clinical Use
Download our brochure